Want to see HK:6855 full AI Analyst Report?
6855 Stock Chart & Stats
HK$50.90
-HK$0.65(-1.60%)
At close: 4:00 PM EST
HK$50.90
-HK$0.65(-1.60%)
Day’s Range― - ―
52-Week RangeHK$27.12 - HK$69.95
Previous CloseN/A
Volume1.20M
Average Volume (3M)2.29M
Market Cap
HK$11.29B
Enterprise ValueHK$12.63B
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 31, 2027EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding374,962,100
10 Day Avg. Volume2,395,901
30 Day Avg. Volume2,293,659
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.00Price Target Upside-11.59% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.84
Revenue Forecast (FY)HK$758.78M
Bulls Say, Bears Say
Bulls Say
Product-led Revenue GrowthGrowing product sales show the company is beginning to convert its oncology pipeline into commercial revenue. Continued adoption of approved medicines can support a more durable revenue base while funding broader commercialization and clinical development.
Approved Products And Advancing PipelineThe combination of two approved products and a broad registrational portfolio creates multiple potential growth drivers. Advancing late-stage programs could expand indications, geographic reach, and future commercial scale beyond the current product base.
Strategic Global PartnershipTakeda’s option provides a credible route to international development and commercialization while potentially sharing execution costs. The upfront, milestone, and royalty structure also gives Ascentage access to external resources and broader global reach.
Bears Say
Heavy Losses And Cash BurnSevere negative cash generation and deep net losses reduce financial flexibility despite revenue growth. If operating losses persist, the company may need continued external funding, which can constrain investment choices and create dilution risk.
Peak Operating ExpenditureLate-stage trial enrollment and commercial expansion are driving a sharp rise in operating costs before the related revenue benefits are fully realized. Sustained spending at these levels could prolong losses and pressure cash resources through the development cycle.
Clinical Execution UncertaintyImportant value-creating milestones remain dependent on completing enrollment and obtaining trial results. Delays, inconclusive data, or weaker outcomes could defer NDA filings, extend spending, and reduce the number of programs able to reach commercialization.
Ascentage Pharma Group International News
6855 FAQ
What was Ascentage Pharma Group International’s price range in the past 12 months?
Ascentage Pharma Group International lowest stock price was HK$27.12 and its highest was HK$69.95 in the past 12 months.
What is Ascentage Pharma Group International’s market cap?
Ascentage Pharma Group International’s market cap is HK$11.29B.
When is Ascentage Pharma Group International’s upcoming earnings report date?
Ascentage Pharma Group International’s upcoming earnings report date is Mar 31, 2027 which is in 157 days.
How were Ascentage Pharma Group International’s earnings last quarter?
Ascentage Pharma Group International released its earnings results on Aug 19, 2026. The company reported -HK$0.634 earnings per share for the quarter, missing the consensus estimate of -HK$0.605 by -HK$0.029.
Is Ascentage Pharma Group International overvalued?
According to Wall Street analysts Ascentage Pharma Group International’s price is currently Overvalued.
Does Ascentage Pharma Group International pay dividends?
Ascentage Pharma Group International does not currently pay dividends.
What is Ascentage Pharma Group International’s EPS estimate?
Ascentage Pharma Group International’s EPS estimate is -0.59.
How many shares outstanding does Ascentage Pharma Group International have?
Ascentage Pharma Group International has 374,962,100 shares outstanding.
What happened to Ascentage Pharma Group International’s price movement after its last earnings report?
Ascentage Pharma Group International reported an EPS of -HK$0.634 in its last earnings report, missing expectations of -HK$0.605. Following the earnings report the stock price went down -0.572%.
Which hedge fund is a major shareholder of Ascentage Pharma Group International?
Currently, no hedge funds are holding shares in HK:6855
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascentage Pharma Group International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$45.00 (-11.59% Downside)
HK$45.00 (-11.59% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.64%
12-Months-Change
Fundamentals
Return on Equity
-153.78%
Trailing 12-Months
Asset Growth
12.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
6855 Stock 12 Month Forecast
Average Price Target
HK$45.00
▼(-11.59% Downside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―